Efficacy of Quetiapine in Generalised Social Anxiety Disorder

Phase 3

Terminated

• Conditions: Social Anxiety Disorder

• Registration Number: NCT00302770
• Lead Sponsor: AstraZeneca

Brief Summary

This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the LSAS

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-03-13
• Study First Submitted QC: 2006-03-13
• Study First Posted: 2006-03-15
• Study Start: 2006-06
• Primary Completion: 2006-12
• Study Completion: 2006-12
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-25
• Last Update Posted: 2011-01-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Written Confirmed Consent,
• All patients meet the DSM IV criteria for generalized social anxiety disorder,
• A score ≥ 60 on the LSAS,
• male and female aged between 18 and 65 years

Exclusion Criteria

• Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV,
• alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,
• any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder,
• patients at risk of suicide

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint

Secondary Outcome Measures

Name	Time	Method
Number of responders, time to onset of response of sustained response to treatment

Trial Locations

Locations (1)

Research Site; 🇳🇱 Utrecht, Netherlands